Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (790)	3/18/1998 8:26:00 PM
From: seminole	Respond to of 1826

Peter <<<So _if_ these studies are comparable, we get complete responses or substantial tumor shrinkage for MGI-114/ITN vs. still pretty rapid tumor growth for the other new combination.>>> My impression of ITN or topotecan (I still don't know the difference between them) is toxicity is a problem in humans. Toxicity in humans is greater than in mice (but not sure). A December issue of Seminars in Oncology was devoted to these Topoisomerase inhibitors. From scanning the abstracts and discussion sections, the hot topic was the search for a drug to combine with the 'tecans'. Maybe, MGI 114 is that drug. The combination is needed to reduce the dose of ITN and reduce the side effects. I am sure the management and employees of MGI are more mature than I am, so I will say it for them...MY DRUG IS BETTER THAN YOUR DRUG. Have a good meeting BMY. richard